These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8958590)

  • 21. Yeast two-hybrid assay for examining human immunodeficiency virus protease heterodimer formation with dominant-negative inhibitors and multidrug-resistant variants.
    Todd S; Laboissière MC; Craik CS
    Anal Biochem; 2000 Jan; 277(2):247-53. PubMed ID: 10625514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constraints on the sequence diversity of the protease of human immunodeficiency virus type 1: a guide for drug design.
    Kaplan AH
    AIDS Res Hum Retroviruses; 1996 Jul; 12(10):849-53. PubMed ID: 8798968
    [No Abstract]   [Full Text] [Related]  

  • 23. Development of a novel screen for protease inhibitors.
    Gillim L; Gusella GL; Vargas J; Marras D; Klotman ME; Cara A
    Clin Diagn Lab Immunol; 2001 Mar; 8(2):437-40. PubMed ID: 11238235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of triazolamers as active site inhibitors of HIV-1 protease.
    Jochim AL; Miller SE; Angelo NG; Arora PS
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6023-6. PubMed ID: 19800230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 protease inhibitors: a comparative QSAR analysis.
    Kurup A; Mekapati SB; Garg R; Hansch C
    Curr Med Chem; 2003 Sep; 10(17):1679-88. PubMed ID: 12871116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.
    Lu D; Sham YY; Vince R
    Bioorg Med Chem; 2010 Mar; 18(5):2037-48. PubMed ID: 20138769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cage dimeric 4-aryl-1,4-dihydropyridines as promising lead structures for the development of a novel class of HIV-1 protease inhibitors.
    Hilgeroth A; Billich A
    Arch Pharm (Weinheim); 1999 Jan; 332(1):3-5. PubMed ID: 10073137
    [No Abstract]   [Full Text] [Related]  

  • 28. Improvement in CD4+ cell counts despite persistently detectable HIV load.
    Levitz SM
    N Engl J Med; 1998 Apr; 338(15):1074-5. PubMed ID: 9537882
    [No Abstract]   [Full Text] [Related]  

  • 29. The cancer-HIV/AIDS treatment conundrum.
    Schmidt C
    J Natl Cancer Inst; 2010 Nov; 102(21):1615-7. PubMed ID: 20966428
    [No Abstract]   [Full Text] [Related]  

  • 30. Sequencing antiretroviral drugs.
    Soriano V
    AIDS; 2001 Mar; 15(5):547-51. PubMed ID: 11316990
    [No Abstract]   [Full Text] [Related]  

  • 31. Risk of new AIDS diseases in people on triple therapy.
    Miller V; Staszewski S; Nisius G; Lepri AC; Sabin C; Phillips AN
    Lancet; 1999 Feb; 353(9151):463. PubMed ID: 9989719
    [No Abstract]   [Full Text] [Related]  

  • 32. No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues.
    Pulido F; Arribas J; Hill A; Moecklinghoff C
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1167-9. PubMed ID: 22380531
    [No Abstract]   [Full Text] [Related]  

  • 33. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 34. Characterization of two structurally novel HIV-1 protease inhibitors identified by rational selection.
    Humblet CC; Lunney EA; Buckheit RW; Doggett C; Wong R; Antonucci TK
    Antiviral Res; 1993 May; 21(1):73-84. PubMed ID: 8317922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The development of anti-HIV-1 drugs.
    Lu XF; Chen ZW
    Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV replication.
    Kingman S
    Mol Med Today; 1995 Apr; 1(1):2. PubMed ID: 9415128
    [No Abstract]   [Full Text] [Related]  

  • 37. AIDS drugs lurch towards market.
    Steele F
    Nat Med; 1995 Apr; 1(4):285-6. PubMed ID: 7585051
    [No Abstract]   [Full Text] [Related]  

  • 38. Human immunodeficiency virus type 1 protease inhibitors.
    McDonald CK; Kuritzkes DR
    Arch Intern Med; 1997 May; 157(9):951-9. PubMed ID: 9140265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.
    Lallemand F; Adda N; Schneider V; Jacomet C; Salhi Y; Rozenbaum W
    Clin Infect Dis; 1999 May; 28(5):1184-5. PubMed ID: 10452672
    [No Abstract]   [Full Text] [Related]  

  • 40. Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy.
    Deeks SG
    Adv Exp Med Biol; 1999; 458():175-82. PubMed ID: 10549390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.